Pre-Anesthetic Administration of Sublingual Buprenorphine for Postoperative Analgesia after Hemorrhoidectomy: A Clinical Trial

1Afsaneh Norouzi, Houshang Talebi, Shaban-ali Alizadeh, Shahin Fatah,
2Ali Mohamadzadeh, Payam Eghtesadi-Araghi and Fatemeh Djamshidi
1Department of Anesthesiology, 2Department of Surgery,
Arak University of Medical Sciences, Arak, Iran
3Department of Anesthesiology, Gilan University of Medical Sciences, Rasht, Iran
4Parsteb Pajouheshy Har Medical Sciences Research Institute, Tehran, Iran
5Arak University of Medical Sciences, Arak, Iran

Abstract: Buprenorphine is classified as an agonist-antagonist mu opioid agonist, which has a longer half-life compared with other opioids. The objective of this study was to evaluate the efficacy of pre-anesthetic administration of buprenorphine on postoperative pain intensity in patients undergoing hemorrhoidectomy. In a prospective, double-blinded, randomized study, 60 ASA I and II subjects with age of 15-65 years scheduled for elective hemorrhoidectomy under general anesthesia were enrolled. They were randomly allocated to receive sublingual buprenorphine (0.4 mg, 30 min before surgery) or placebo. All the patients were anaesthetized with halothane N\textsubscript{2}O/O\textsubscript{2} after induction with thiopentone. Pain scores, as assessed by a visual analog scale, were evaluated immediately, 2, 4 and 6 h postoperatively. Total dose of analgesics and time of the first request for an analgesic medication were measured as well. The pain scores in the buprenorphine group were similar to that in control group immediately and 2 h postoperatively. The postoperative pain intensities in 4 and 6 h following surgery were significantly lower in patients receiving buprenorphine compared with control groups (3.83±2.50 vs. 5.27±2.63 and 1.60±2.63 vs. 4.40±2.59, respectively). Patients in buprenorphine group have a significantly longer time to first analgesic request (3.59±0.82 vs. 1.90±0.64 h); however, groups were comparable regarding total dose of analgesic consumption.

Key words: Buprenorphine, postoperative pain, hemorrhoidectomy, randomized, pre-anesthetic, administration

INTRODUCTION

Buprenorphine is classified as a partial mu-opioid agonist (Pick et al., 1997). It has a high affinity, but low efficacy at the mu receptor, where it yields a partial effect upon binding (Helm et al., 2008). Buprenorphine has a poor bioavailability due to significant first-pass metabolism in the liver after oral administration (Cowan et al., 1977). Conversely, because of high lipid solubility, it has an excellent sublingual bioavailability. Following the sublingual administration of 0.4 or 0.8 mg doses, the time to maximum concentration was variable, ranging from 90-360 min (Bullingham et al., 1981; Watson et al., 1982) and duration of action of 8-12 h (Broedel et al., 1997). The average systemic bioavailability was 55%, with large intersubject variability. It is used on a once-a-day dose for maintenance therapy (Helm et al., 2008). Buprenorphine has been in clinical use for over 25 years (Johnson et al., 2005).

It has been used as an analgesic in several studies, however, 3 are limited studies evaluating the post-surgical analgesic properties of preoperative administration of Buprenorphine. To our knowledge, there is only one study in which the effects of preoperative sublingual buprenorphine have been assessed on postoperative pain, the need for postoperative opioid injections and on time to discharge in human being (Juhlin-Dannfelt et al., 1995). In another study, it has been shown that the preoperative use of buprenorphine jelly is easy to use and causes post-surgical analgesia in rats (Fleckenell et al., 1999).

The objective of this study was, to evaluate the efficacy of pre-anesthetic administration of buprenorphine on postoperative pain intensity, in patients undergoing hemorrhoidectomy.
MATERIALS AND METHODS

Sixty adult patients with American Society of Anesthesiologists (ASA) physical status I or II were enrolled in a prospective, randomized, double-blinded study, following approval of ethical committee of Arak University of Medical Sciences and obtaining written informed consent and underwent general anesthesia for elective hemorrhoidectomy. Patients with chronic pain, daily intake of analgesics, suffering from liver disease or treated with antiepileptic drugs, unable to cooperate or with a record of drug or alcohol abuse were excluded from the study.

Using a table of random numbers, patients were randomly assigned to 2 groups of Buprenorphine (Buprenorphine tablet 0.4 mg, manufactured by Darbandar Pan Drug Production and Distribution Company) or control (placebo). Both groups received their tablets sublingually, 30 min before surgery.

All patients were premedicated with fentanyl 2-3 μg kg⁻¹ before induction of anesthesia. Under standard monitoring, general anesthesia was induced with thiopentone 4 mg kg⁻¹ and additional 50 mg doses until disappearance of the cilary reflex. Succinylcholine 1 mg kg⁻¹ was used for neuromuscular blockade. Anesthesia was maintained with 1-1.5 MAC (inspiratory saturation) of Halothane in O₂ and N₂O (50%) with spontaneous ventilation. Then the subjects were transported to the Post Anesthesia Care Unit (PACU) and next to the ward for the remainder of the study period. After transferring the patient to the PACU and surgery ward, 25 mg of meperidine was administered IV upon each request of the patient for analgesics.

The intensity of the pain was evaluated on a 10 cm Visual Analogue Scale (VAS) (from 0, which means no pain sensation, to 10 as the most intense pain the patient has ever experienced), in the PACU, 2, 4 and 6 h following completion of surgery by a single independent investigator blinded to subject group assignment.

The pain intensity, time to the first request for rescue analgesics and the total dose of it during the first 6 h were recorded and compared between groups.

Data are expressed as mean±SD or number of patients. Parametric data were analyzed using independent samples t-test. For categorical data analysis chi-square (χ²) or Fisher’s exact test was utilized as appropriate. Statistical calculations were performed utilizing SPSS (SPSS Inc., Chicago, Illinois, USA) version 12.0. Differences were considered significant at p<0.05.

<table>
<thead>
<tr>
<th>Table 1: Subjects clinical data</th>
<th>Control</th>
<th>Buprenorphine</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pain</td>
<td>8.7±2.30</td>
<td>8.9±2.57</td>
<td>0.8700</td>
</tr>
<tr>
<td>2 h</td>
<td>7.0±2.30</td>
<td>5.7±2.80</td>
<td>0.0540</td>
</tr>
<tr>
<td>4 h</td>
<td>5.2±2.60</td>
<td>3.8±2.50</td>
<td>0.0300</td>
</tr>
<tr>
<td>6 h</td>
<td>4.4±2.50</td>
<td>1.6±2.65</td>
<td>0.0001</td>
</tr>
<tr>
<td>Pathine dose (mg)</td>
<td>35±3±12.92</td>
<td>32.0±9.88</td>
<td>0.2800</td>
</tr>
<tr>
<td>Time to first analgesic request (h)</td>
<td>1.9±0.66</td>
<td>3.5±0.82</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Data are represented as mean±SD; †: Post Anesthesia Care Unit; +: Significant difference, t-test</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

were male. There were no significant differences among groups demographic data.

The pain intensities were comparable among groups in PACU and second hour following surgery. However, its intensity was significantly lower in Buprenorphine group, both in 4th and 6th h postoperatively (Table 1).

While patients in Buprenorphine group have a significantly longer time to first analgesic request, both groups were comparable regarding total dose of analgesic consumption (Table 1). All the patients experienced uneventful recoveries.

DISCUSSION

This study showed that administration of Buprenorphine 0.4 mg sublingually significantly reduced the pain intensities, 4 and 6 h following surgery and lengthened the duration to first time analgesic request. Yet, it did not make any changes in the total dose of postoperative analgesic consumption.

As a supplement to anesthesia, buprenorphine has been used successfully in dosages ranging from 2-40 μg kg⁻¹ (Kay, 1980; McQuay et al., 1980; Pedersen et al., 1986). It was as effective as morphine in dogs (Brodbelt et al., 1997), with greater duration of postoperative analgesia and potency than could be achieved with morphine, in human subjects (Bradley, 1984). Compared with meperidine, buprenorphine was shown to be a satisfactory analgesic for preoperative and postoperative use with little difference in the incidence of unwanted effects and much longer duration of action (Khan and Kamal, 1990; Watanabe et al., 1994). There are other studies supporting the analgesic properties of buprenorphine in human subjects (Bradley, 1984; Hammital et al., 1996; Satoh et al., 1994).

Sublingual application of buprenorphine offers an effective and easy alternative to the parenteral route of prescription, especially for the management of postoperative pain (Gaitini et al., 1996; Lacote et al., 1997). Despite the efficacy and safety of sublingual buprenorphine has been demonstrated as an analgesic for postoperative analgesia (Lebedeva et al., 1996), there are limited studies in which buprenorphine given by this root
of administration have been studied as premedication. Risbo et al. (1985) revealed that sublingually administered buprenorphine is as good as intramuscular morphine for premedication. In consistence with the results of Juhlin-Dannfelt (1995), the results of the present study revealed that premedication with sublingual buprenorphine reduces the pain intensities postoperatively and the need for postoperative injections of pethidine. Consequently, it should be recommended to patients who wish to avoid injections. These effects are derived from its mu-opioid agonist's activities. However, unlike full mu-opioid agonists, at higher doses, buprenorphine's physiological and subjective effects, including euphoria, reach a plateau. This ceiling may result in a wider safety margin (Johnson et al., 2005).

Although, a precise explanation for this phenomenon is lacking, its analgesic activity is not directly related to its dosage. In one trial undertaken on patients undergoing biliary surgery (Pedersen et al., 1986), while none of the patients receiving 10-20 μg kg⁻¹ needed an analgesic within 1 h of the operation, half of the patients who received 30-40 μg kg⁻¹ buprenorphine requested an analgesic within 5 min of extubation. To a certain extent, these findings are consistent with the presence of a bell-shaped dose-response curve for buprenorphine in humans.

Only minor and unimportant side effects were seen (Risbo et al., 1985). Usual adverse effects following buprenorphine administration may include sedation, nausea and/or vomiting, dizziness, headache and respiratory depression (Helm et al., 2008). Among them, nausea and vomiting may prolong the recovery time. The higher incidence of nausea was the main reason that Juhlin-Dannfelt et al. (1995) did not recommend sublingual buprenorphine for out-patient arthroscopy. Unfortunately, we were not able to compare the nausea, vomiting and other adverse effects between groups. Respiratory depression may occur and may not be responsive to treatment with naloxone; however, as a mu-opioid partial agonist with a demonstrated ceiling on respiratory depression, buprenorphine may have a better safety profile compared to full mu agonists (Johnson et al., 2005).

CONCLUSION

In conclusion, it seems that sublingually administered buprenorphine significantly reduces the postoperative pain intensities and increases time to first time analgesic request; however, no changes in consumption of postoperative analgesics are observed.

ACKNOWLEDGEMENT

This manuscript was adopted from the M.D. thesis of Fatemeh Djamshidi that was approved by the Institutional Review Board of Arak University of Medical Sciences (Arak, Iran) and was conducted in Anesthesiology and Critical Care Medicine department of Arak University of Medical Sciences (Arak, Iran) and had no financial support. The authors wish to thank Dr. Golnar Mortezaie, for her invaluable assistance.

REFERENCES


229


230